Extended dicer substrate agents and methods for the specific inhibition of gene expression
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
1. A double stranded nucleic acid (dsNA) for reducing expression of a target RNA comprising:
an antisense strand that comprises a 3′ terminus and a 5′ terminus, wherein said antisense strand is 21 nucleotides in length, wherein at least 13 of the nucleotides comprise a 2′-O-methyl modified sugar moiety, wherein at least one of the nucleotides comprises a 2′-fluoro modified sugar moiety, and wherein a phosphate backbone of said antisense strand comprises at least one phosphorothioate modification,
a sense strand that comprises a 3′ terminus and a 5′ terminus, wherein said sense strand is 21 nucleotides in length, wherein at least 18 of the nucleotides comprise a 2′-O-methyl modified sugar moiety, wherein at least one of the nucleotides comprises a 2′-fluoro modified sugar moiety, wherein a phosphate backbone of said sense strand comprises at least one phosphorothioate modification, wherein said sense strand comprises one or more inverted abasic residues, and wherein said sense strand is conjugated to a non-nucleic acid moiety or an organic compound,
wherein said antisense strand is annealed to said sense strand to form a duplex region of 21 nucleotides in length,
wherein said antisense strand is sufficiently complementary to said target RNA to reduce expression of said target RNA.
2. The dsNA of claim 1 , wherein one or both of said antisense and sense strands comprise a 5′ phosphate.
3. The dsNA of claim 1 , wherein said antisense strand comprises one or more patterns of alternating nucleotides that comprise said 2′-O-methyl modified sugar moiety.
4. The dsNA of claim 1 , wherein said antisense strand comprises one or more patterns of alternating nucleotides that comprise said 2′-O-methyl modified sugar moiety and said 2′-fluoro modified sugar moiety.
5. The dsNA of claim 1 , wherein all of the nucleotides are modified and comprise a 2′-O-methyl modified sugar moiety or a 2′-fluoro modified sugar moiety.
6. The dsNA of claim 1 , wherein said antisense strand is 100% complementary to said target RNA.
7. The dsNA of claim 1 , wherein said dsNA forms one or more blunt ends.
8. The dsNA of claim 1 , further comprising a modified nucleotide that is, or comprises a moiety, selected from the group consisting of: a peptide nucleic acid (PNA), dideoxyribonucleotides, acyclonucleotides 3′-deoxyadenosine (cordycepin), 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxy-3′-thiacytidine (3TC), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), the monophosphate nucleotides of 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxy-3′-thiacytidine (3 TC), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), 2′-methoxyethoxy, 2′-fluoro, 2′-allyl, 2′-O[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge, 4′-(CH2)2-O-2′-bridge, 2′-LNA, 2′-amino, 2′-O-(N-methylcarbamate), a methylphosphonate modification, a phosphotriester modification, a base analog, and an LNA modification.
9. A pharmaceutical composition for reducing expression of said target gene in said mammalian cell comprising said dsNA of claim 1 and a pharmaceutically acceptable carrier.
10. The dsNA of claim 1 , wherein said sense strand comprises one or more patterns of alternating nucleotides that comprise said 2′-O-methyl modified sugar moiety.
11. The dsNA of claim 1 , wherein pyrimidines of said antisense strand are 2′-fluoro modified.
12. The dsNA of claim 1 , wherein purines of said antisense strand are 2′-fluoro modified.
13. The dsNA of claim 1 , wherein pyrimidines of said sense strand are 2′-fluoro modified.
14. The dsNA of claim 1 , wherein purines of said sense strand are 2′-fluoro modified.
15. The dsNA of claim 1 , wherein purines of said antisense strand are 2′-O-methyl modified.
16. The dsNA of claim 1 , wherein purines of said sense strand are 2′-O-methyl modified.
17. The dsNA of claim 1 , wherein said antisense strand includes one or more inverted abasic residues.
18. The dsNA of claim 1 , wherein said phosphorothioate modification of said antisense strand is a 3′-terminal phosphorothioate linkage.
19. The dsNA of claim 1 , wherein said phosphorothioate modification of said sense strand is a 3′-terminal phosphorothioate linkage.
20. The dsNA of claim 1 , wherein said antisense strand is conjugated at its 5′ or 3′-terminus to a non-nucleic acid moiety or an organic compound.